Petry Nancy M, Roll John M, Rounsaville Bruce J, Ball Samuel A, Stitzer Maxine, Peirce Jessica M, Blaine Jack, Kirby Kimberly C, McCarty Dennis, Carroll Kathleen M
Calhoun Cardiology Center, Department of Medicine, University of Connecticut Health Center, USA.
J Consult Clin Psychol. 2008 Dec;76(6):1076-82. doi: 10.1037/a0013679.
Human subjects protection policies developed for pharmaceutical trials are now being widely applied to psychosocial intervention studies. This study examined occurrences of serious adverse events (SAEs) reported in multicenter psychosocial trials of the National Institute on Drug Abuse Clinical Trials Network. Substance-abusing participants (N = 1,687) were randomized to standard care or standard care plus either contingency management or motivational enhancement. Twelve percent of participants experienced 1 or more SAEs during the 27,198 person-weeks of follow-up. Of the 260 SAEs recorded, none were judged by the data safety monitoring board to be study related, and there were no significant differences between experimental and control conditions in SAE incidence rates. These data underscore the need to reconsider the rationale behind, and appropriate methods for, monitoring safety during psychosocial therapy trials.
为药物试验制定的人体受试者保护政策现在正广泛应用于心理社会干预研究。本研究调查了美国国立药物滥用研究所临床试验网络多中心心理社会试验中报告的严重不良事件(SAE)的发生情况。药物滥用参与者(N = 1687)被随机分配接受标准护理或标准护理加应急管理或动机增强。在27198人周的随访期间,12%的参与者经历了1次或更多次SAE。在记录的260次SAE中,数据安全监测委员会判定没有一次与研究相关,并且SAE发生率在实验条件和对照条件之间没有显著差异。这些数据强调了重新考虑心理社会治疗试验期间监测安全性的基本原理和适当方法的必要性。